We subsequently proved that serum FOLR1 levels can serve as a novel biomarker for HCC detection and prognostic predictions of early-stage HCC, suggesting potential utility for improved risk stratification and personalized treatment strategies. Here, FOLR1 is linked to hepatocellular carcinoma.